Graft-versus-host disease: A surge of developments
Author Information
Author(s): Stanley Riddell, Frederick Appelbaum
Primary Institution: Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine
Hypothesis
Can we prevent graft-versus-host disease (GVHD) without increasing other transplant complications?
Conclusion
Recent advancements in HLA-typing and donor selection may significantly reduce the risk of developing severe GVHD.
Supporting Evidence
- Approximately 50% of patients receiving HCT will develop acute GVHD.
- Improvements in HLA-typing technology have reduced the incidence of severe GVHD.
- Recent studies suggest that manipulating T cell subsets in grafts can reduce GVHD.
Takeaway
When people get a special type of transplant, their body can sometimes react badly. Scientists are finding better ways to pick donors to help prevent these bad reactions.
Methodology
The review discusses various studies and advancements in preventing GVHD following allogeneic hematopoietic cell transplantation.
Limitations
The review is based on existing studies and may not include the latest research findings.
Participant Demographics
Approximately 20,000 individuals receiving allogeneic hematopoietic cell transplants.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website